Who are Statin plus niacin ER/laropiprant's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/statin-plus-niacin-er-laropiprant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Statin plus niacin ER/laropiprant — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Statin plus niacin ER/laropiprant (Statin plus niacin ER/laropiprant) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Statin combined with niacin ER and DP1 antagonist. Area: Cardiovascular.

marketed Statin combined with niacin ER and DP1 antagonist HMG-CoA reductase (statin component); GPR109A/PUMA-G (niacin component); DP1 receptor (laropiprant component) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Statin plus niacin ER/laropiprant (Statin plus niacin ER/laropiprant) — University of Ioannina. A combination therapy that lowers LDL cholesterol via statin action while niacin ER/laropiprant raises HDL cholesterol and reduces triglycerides, with laropiprant blocking prostaglandin D2 receptors to reduce niacin-induced flushing.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Statin plus niacin ER/laropiprant TARGET	Statin plus niacin ER/laropiprant	University of Ioannina	marketed	Statin combined with niacin ER and DP1 antagonist	HMG-CoA reductase (statin component); GPR109A/PUMA-G (niacin component); DP1 receptor (laropiprant component)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Statin combined with niacin ER and DP1 antagonist class)

University of Ioannina · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Statin plus niacin ER/laropiprant — Competitive Intelligence Brief. https://druglandscape.com/ci/statin-plus-niacin-er-laropiprant. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab